Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P11487
UPID:
FGF3_HUMAN
Alternative names:
Heparin-binding growth factor 3; Proto-oncogene Int-2
Alternative UPACC:
P11487; Q0VG69
Background:
Fibroblast growth factor 3 (FGF3), also known as Heparin-binding growth factor 3 and Proto-oncogene Int-2, plays a pivotal role in embryonic development, cell proliferation, and differentiation. It is essential for normal ear development, highlighting its significance in auditory system formation.
Therapeutic significance:
FGF3 is linked to a unique autosomal recessive syndrome characterized by deafness with labyrinthine aplasia, microtia, and microdontia. This association underscores the protein's critical role in ear development and presents it as a potential target for therapeutic intervention in related congenital disorders.